Anthony Chuang, DO
Internal Medicine · Albuquerque, NMNPI 1891082327
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,267, more than ten times the $144 reported in 2019. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$773
- Novo Nordisk$663
- Amgen$506
- Dexcom, Inc.$353
- Lilly USA, LLC$320
- Xeris Pharmaceuticals, Inc.$312
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,31397%
- Education$1683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $773 |
| Novo Nordisk | 35 | $663 |
| Amgen(2 entities) | 20 | $506 |
| Dexcom, Inc. | 18 | $353 |
| Lilly USA, LLC | 21 | $320 |
| Xeris Pharmaceuticals, Inc. | 13 | $312 |
| Corcept Therapeutics | 11 | $281 |
| Tandem Diabetes Care, Inc. | 8 | $261 |
| Mannkind Corporation | 16 | $255 |
| Medtronic | 2 | $206 |
| Bayer | 10 | $187 |
| AbbVie | 9 | $148 |
| Insulet Corporation | 2 | $145 |
| Sanofi-aventis U.S. LLC | 5 | $136 |
| Astellas Pharma US Inc | 1 | $118 |
| Intersect ENT, Inc. | 1 | $115 |
| Sequel Med Tech, LLC | 5 | $114 |
| Ultragenyx Pharmaceutical Inc. | 2 | $99 |
| Amneal Pharmaceuticals LLC | 3 | $71 |
| Neurocrine Biosciences, Inc. | 2 | $53 |
| Boehringer Ingelheim | 2 | $48 |
| AstraZeneca | 2 | $40 |
| IBSA Pharma Inc. | 2 | $30 |
| Pfizer | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Masimo Corporation | 1 | $20 |
| Avvisto Therapeutics, LLC | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$532
- MINIMED 780G$183
- Omnipod$125
- t:slim X2 Insulin Pump with Control-IQ$124
- DEXCOM G7 GSS (161)$119
- Veozah$118
- SINUVA$115
- PROPEL$115
- EVENITY$109
- GVOKE HYPOPEN$107
How this compares
$5,482 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $232,367 |
| Tresiba Flextouch U-100Insulin Degludec | 103 | $76,017 |
| MounjaroTirzepatide | 53 | $56,404 |
| JardianceEmpagliflozin | 61 | $54,248 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $52,542 |
| FarxigaDapagliflozin Propanediol | 52 | $43,891 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $35,993 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $30,701 |
| RybelsusSemaglutide | 29 | $28,613 |
| TrulicityDulaglutide | 14 | $23,589 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $19,620 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 15 | $14,210 |
| Novolog FlexpenInsulin Aspart | 50 | $11,684 |
| Humalog Kwikpen U-100Insulin Lispro | 44 | $11,164 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $10,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $663 | $260,980208 claims |
| Lilly USA, LLCMounjaro, Trulicity | $320 | $79,99367 claims |
| Boehringer IngelheimJardiance | $48 | $54,24861 claims |
| AstraZenecaFarxiga | $40 | $43,89152 claims |
| Sanofi-aventis U.S. LLCLantus | $136 | $1,97812 claims |
| AbbVieSynthroid | $148 | $1,88622 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $1,482164 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $21 | $38013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.